// App-Quantinova.ai

: Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from two Phase III trials

Researchers

Presenter

  • Kim Papp

Principal Investigators

  • Ahmed M. Soliman

  • Christian Kaufmann

  • Lisa Barcomb

  • Zailong Wang

  • Douglas White

  • Andrew Ostor

  • Lars Erik Kristensen

Medical Centers

  • Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada

  • AbbVie, Inc., North Chicago, IL

  • Rheumatology Department, Waikato Hospital, Hamilton, New Zealand

  • Cabrini Hospital, Monash University & Emeritus Research Melbourne, Melbourne, Australia

  • The Finsen Center, Copenhagen University Hospital, Copenhagen, Denmark

Locations

  • Canada

  • New Zealand

  • United Kingdom

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Risankizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved